TriSalus Life Sciences, Inc. Notes Payable, Current
TriSalus Life Sciences, Inc. (TLSI) had Notes Payable, Current of $1.57 million as of 2023-06-30, per its 10-Q filed 2023-08-02.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:NotesPayableCurrent · last filed 2023-08-02
- 2023-06-30: Notes Payable, Current $1.57M.
- 2022-12-31: Notes Payable, Current $944.00K.
| Period end | Notes Payable, Current |
|---|---|
| 2023-06-30 | $1.57M 10-Q · filed 2023-08-02 |
| 2022-12-31 | $944.00K 10-Q · filed 2023-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |